Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension Ghofrani HA; Pepke-Zaba J; Barbera JA; Channick R; Keogh AM; Gomez-Sanchez MA; Kneussl M; Grimminger FJ Am Coll Cardiol 2004[Jun]; 43 (12 Suppl S): 68S-72SPulmonary hypertension (PH) is a disease of various origins. Nitric oxide-a potent vasodilator-is a key player of pulmonary vasoregulation. Nitric oxide signaling is mainly mediated by the guanylate cyclase/cyclic guanylate monophosphate pathway. The effects of this second messenger system are limited by enzymatic degradation through phosphodiesterases (PDEs). Recently, beneficial effects of the oral PDE-5 inhibitor sildenafil (originally approved for the treatment of erectile dysfunction) were reported for the treatment of PH. We provide a brief overview of the experimental and clinical application of PDE inhibitors in the field of PH. In particular, studies reporting the clinical effectiveness of sildenafil are highlighted. This agent, despite oral application, displays characteristics of a pulmonary selective vasodilator. In addition, evidence shows that sildenafil is operative mainly in the vasculature of well-ventilated areas of the lung. However, to date, controlled randomized trials proving the efficacy of this approach for the treatment of pulmonary arterial hypertension are lacking. The results of such studies have to confirm the current encouraging findings before recommendations regarding the use of PDE-5 inhibitors as a new treatment for PH can be made.|Animals[MESH]|Endothelium, Vascular/drug effects/metabolism[MESH]|Humans[MESH]|Hypertension, Pulmonary/*drug therapy/*metabolism[MESH]|Nitric Oxide/*metabolism[MESH]|Phosphodiesterase Inhibitors/*therapeutic use[MESH]|Piperazines/therapeutic use[MESH]|Pulmonary Artery/*drug effects/*metabolism/*pathology[MESH]|Purines[MESH]|Sildenafil Citrate[MESH]|Sulfones[MESH]|Vasodilator Agents/therapeutic use[MESH] |